申请人:Zeneca Limited
公开号:US05527791A1
公开(公告)日:1996-06-18
The present invention provides a compound of the formula: ##STR1## or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof wherein: A is a group of the formula (IA) or (IB): ##STR2## R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; R.sup.3 and R.sup.4 are the same or different and are a variety of substituents X is alkanediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x (wherein x is zero, one or two), --CONR.sup.5 -- or --NR.sup.5 -- or wherein R.sup.5 is hydrogen or C.sub.1-4 alkyl; or X is alkenediyl containing 1-6 carbon atoms optionally interrupted by O, S(O).sub.x or --NR.sup.5 --.
本发明提供了以下式的化合物:##STR1##或其药学上可接受的盐或体内可水解的酯,其中:A是式(I A)或(IB)的基团:##STR2##R.sup.1是1-羟乙基、1-氟乙基或羟甲基;R.sup.2是氢或C.sub.1-4烷基;R.sup.3和R.sup.4相同或不同,是各种取代基;X是含有1-6个碳原子的烷基,可选择地由O、S(O).sub.x(其中x为零、一或二)、--CONR.sup.5--或--NR.sup.5--中断;或其中R.sup.5是氢或C.sub.1-4烷基;或X是含有1-6个碳原子的烯烃基,可选择地由O、S(O).sub.x或--NR.sup.5--中断。